Skip to main content
Future Medicine Co., Ltd. logo

Future Medicine Co., Ltd. — Investor Relations & Filings

Ticker · 341170 ISIN · KR7341170009 KO Manufacturing
Open in API
Filings indexed 93 across all filing types
Latest filing 2026-02-13 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 341170

About Future Medicine Co., Ltd.

http://futuremedicine.co.kr/

Future Medicine Co., Ltd. is a new drug development company specializing in nucleoside-based synthetic drugs. The company focuses on creating therapeutics for diseases with high unmet medical needs, particularly in antiviral and anticancer applications. Its primary pipeline candidate, FM101, is an anti-inflammatory and anti-fibrotic agent being investigated for the treatment of conditions such as non-alcoholic steatohepatitis (NASH), diabetic nephropathy, and primary biliary cholangitis (PBC). The company has also conducted research and filed patents for therapeutics related to coronaviruses.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a decision on a paid-in capital increase (유상증자결정) and a subsequent amendment (정정신고) to that filing. In the context of Korean corporate filings (DART system), these are regulatory disclosures regarding capital structure changes. Since it specifically details the issuance of new shares, pricing, and allocation, it falls under the 'Share Issue/Capital Change' category.
2026-02-13 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a decision on a paid-in capital increase (유상증자결정) by Future Medicine. It details the amendment of payment dates and share issuance terms. This type of filing, which concerns capital structure changes and share issuance, is classified as 'Share Issue/Capital Change' (SHA) in the provided schema.
2026-02-13 Korean
[기재정정]주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 1% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a decision on a third-party paid-in capital increase (유상증자결정). It details the issuance of new shares, the purpose of the capital raise, the identity of the third-party investor (NK Therapeutics Corp), and the impact on shareholding structure. This falls under the category of capital structure changes and financing activities.
2026-01-05 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정). It details the amendment of payment dates and listing dates for a third-party allocation capital increase. This type of filing is a standard regulatory disclosure for capital changes in the Korean market, which falls under the 'Share Issue/Capital Change' category.
2026-01-05 Korean
기업설명회(IR)개최
Regulatory Filings
2025-11-11 Korean
기업설명회(IR)개최결과
Regulatory Filings Classification · 1% confidence The document is a short, structured announcement detailing the results of an Investor Relations (IR) meeting held by Future Medicine. It lists the date, location, attendees, and agenda items, and provides a link to the IR materials on the KRX website. Since it is a brief notification of an event and the availability of materials rather than the presentation deck itself, it falls under the category of a regulatory filing announcement.
2025-06-23 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.